Treatment of Wilson's disease with triethylene tetramine hydrochloride (Trientine).
Penicillamine is the drug of choice for the treatment of Wilson's disease, whatever the stage of the illness. Toxic manifestations may preclude the use of this life-saving drug in some patients and discontinuation of penicillamine therapy usually leads to death. We report our experience with Trientine in seven patients, aged 13 to 33 years, with Wilson's disease who developed toxic manifestations with penicillamine that required discontinuation of therapy. These include two with nephrosis, one with neutropenia, two with thrombocytopenia, and one each with a SLE-like and a Henoch-Schonlein-like syndrome. The patients were treated for periods from 6 weeks to 16 years with a dose of 0.5 to 2 g/day. Trientine proved to be an effective alternative copper chelating agent in the treatment of Wilson's disease in patients with penicillamine-induced neutropenia, thrombocytopenia, SLE, and nephrosis. No serious untoward side effects were noted.
Dubois
R S
RS
Department of Pediatrics, Wayne State University, School of Medicine, Detroit, Michigan.
Rodgerson
D O
DO
Hambidge
K M
KM
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D004341:Drug Evaluation; D005029:Ethylenediamines / Q000627:therapeutic use*; D005260:Female; D006527:Hepatolenticular Degeneration / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010396:Penicillamine / Q000506:poisoning* / Q000627:therapeutic use; D014266:Trientine / Q000008:administration & dosage / Q000627:therapeutic use*
D005029:Ethylenediamines; D010396:Penicillamine; D014266:Trientine